The signaling pathways triggered by IL-4 and IL-13 recruit two distinct heterodimeric IL-4 receptors, type I IL-4R (comprising IL-4R and the c common cytokine receptor chains) and type II IL-4R (comprising IL-4R and IL-13R1 chains)
HDAC inhibitors are agents that effectively reduce histone deacetylation
Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Similar studies with erythropoietin would show hematological effects at far lower multiples
Diabetes Ther 12, 13251339 (2021)
